{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:41:18Z","timestamp":1792611678961,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Few challenges are faced with the introduction of anti-VEGF agents as a modality of treatment for retinopathy of prematurity. The clinical behavior and time course of regression post injection differ compared to post laser ablation. This study aims to evaluate the long-term peripheral retinal vascularization outcome of Ranibizumab intravitreal injections monotherapy in the treatment of retinopathy of prematurity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Hospital-based quasi-experimental study. Include ROP patients who received intravitreal ranibizumab (IVR), as primary treatment for type 1 ROP. Patients were examined under general anaesthesia to ensure documentation of all junctions of vascular and avascular zones. Images were taken by RetCam III, Phoenix ICON and fluorescein angiography was performed to describe vascular behaviors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean gestational age was 24.67\u00a0weeks and the mean postmenstrual age at the time of intravitreal ranibizumab treatment was 36.3\u00a0weeks. Fluorescein angiography was performed at 155\u2013288\u00a0weeks; most eyes showed two disk diameters of avascular peripheral retina. Only eyes with original aggressive ROP who required a second injection (six eyes) showed extensive peripheral avascular retina reaching zone I (13.64%). Neovascularization was evident in five eyes (11.36%), all with an original aggressive ROP and received multiple injections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ranibizumab treated babies with incomplete retinal vascularization require close and long-term follow-up visits to assess post injection vascular behavior. Peripheral retinal avascular zone of more than two-disc diameters was present in most of the patients evidenced by fluorescein angiography. Babies with initial diagnosis of aggressive ROP are more likely to have persistent peripheral neovascularization.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-022-00402-3","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T11:18:15Z","timestamp":1659439095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography"],"prefix":"10.1186","volume":"8","author":[{"given":"Raghad","family":"Al Rasheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Idrees","family":"Adhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Abdullah","family":"Alowedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan","family":"Albdah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Aldebasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Hazzazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"402_CR1","unstructured":"McCannel C, Atebara N, Kim S, et al. Chapter 8: Retinopathy of Prematurity. Basic Clinical and Science Course Section 12: Retina and Vitreous. San Francisco, CA: AAO. 2018\u20132019; 175\u2013187"},{"key":"402_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","volume":"16","author":"MP Blair","year":"2012","unstructured":"Blair MP, Shapiro MJ, Hartnett ME. Fluorescein angiography to estimate normal peripheral retinal non perfusion in children. J AAPOS. 2012;16:234\u20137.","journal-title":"J AAPOS"},{"issue":"7","key":"402_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"402_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684\u201394.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"402_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mints-Hittner","year":"2011","unstructured":"Mints-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of Intravitreal Bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"10208","key":"402_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomized controlled trial. Lancet. 2019;394(10208):1551\u20139.","journal-title":"Lancet"},{"issue":"21","key":"402_CR7","doi-asserted-by":"publisher","first-page":"00416","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"S0161\u20136420","author":"MF Chiang","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity. Third Edition Ophthalmol. 2021;S0161\u20136420(21):00416\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.031.","journal-title":"Third Edition Ophthalmol"},{"key":"402_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2012.12.017","volume":"17","author":"MM Geloneck","year":"2013","unstructured":"Geloneck MM, Chan JD, Chuang AZ, Mintz-Hittner HA. BEATROP refraction data at age 2 years. J AAPOS. 2013;17: e5.","journal-title":"J AAPOS"},{"key":"402_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jaapos.2009.12.002","volume":"14","author":"HA Mintz-Hittner","year":"2010","unstructured":"Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS. 2010;14:2\u20133.","journal-title":"J AAPOS"},{"key":"402_CR10","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","volume":"23","author":"B Toy","year":"2016","unstructured":"Toy B, Schachar I, Tan G, Moshfeghi D. Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity. Ophthalmol. 2016;23:2166\u201375.","journal-title":"Ophthalmol"},{"key":"402_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3928\/23258160-20161219-11","volume":"48","author":"S Day","year":"2017","unstructured":"Day S, Rainey AM, Harper CA. Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity. Ophthalmol Surg Lasers Imaging Retina. 2017;48:75\u20138.","journal-title":"Ophthalmol Surg Lasers Imaging Retina"},{"key":"402_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"R Wong","year":"2015","unstructured":"Wong R, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35:675\u201380.","journal-title":"Retina"},{"issue":"2","key":"402_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018;125(2):218\u201326.","journal-title":"Ophthalmology"},{"issue":"7","key":"402_CR14","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.18240\/ijo.2019.07.15","volume":"12","author":"QY Meng","year":"2019","unstructured":"Meng QY, Cheng Y, Zhao MW, Liang JH. The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China. Int J Ophthalmol. 2019;12(7):1146\u201350.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"402_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.18240\/ijo.2019.01.12","volume":"12","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Liu TG, Li WY, Zhao MW, Liang JH. Fluorescein angiography of retinal vascular involution after intravitreal injection of ranibizumab for retinopathy of prematurity. Int J Ophthalmol. 2019;12(1):79\u201382. https:\/\/doi.org\/10.18240\/ijo.2019.01.12.","journal-title":"Int J Ophthalmol"},{"key":"402_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1136\/bjo.2005.078063","volume":"90","author":"Y Chen","year":"2006","unstructured":"Chen Y, Li X. Characteristics of severe retinopathy of prematurity patients in China: a repeat of the first epidemic. Br J Ophthalmol. 2006;90:268\u201371.","journal-title":"Br J Ophthalmol"},{"key":"402_CR17","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121:2212\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"402_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi- Darida M. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity. A longitudinal fluorescein angiographic study. Retina. 2017;37(1):97\u2013111.","journal-title":"Retina"},{"issue":"3","key":"402_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/14767058.2012.712313","volume":"25","author":"V Purcaro","year":"2012","unstructured":"Purcaro V, Baldascino A, Papacci P, et al. Fluorescein angiography and retinal vascular development in premature infants. J Matern Fetal Neonatal Med. 2012;25(3):53\u20136. https:\/\/doi.org\/10.3109\/14767058.2012.712313.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"402_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12886-018-0815-1","volume":"18","author":"Q Tong","year":"2018","unstructured":"Tong Q, Yin H, Zhao M, Li X, Yu W. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab. BMC Ophthalmol. 2018;18(1):150.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"402_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","volume":"42","author":"M Gunay","year":"2017","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in turkey. Curr Eye Res. 2017;42(3):462\u20139.","journal-title":"Curr Eye Res"},{"key":"402_CR22","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013;91:e74\u20135.","journal-title":"Acta Ophthalmol"},{"issue":"14","key":"402_CR23","first-page":"3165","volume":"52","author":"SJ Lee","year":"2011","unstructured":"Lee SJ, Kim SY, Yoo BC, et al. Plasma level of vascular endothelial growth factor in retinopathy of prematurity after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2011;52(14):3165.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"402_CR24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831\u20138.","journal-title":"Retina"},{"issue":"3","key":"402_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","volume":"124","author":"J Feng","year":"2017","unstructured":"Feng J, Qian J, Jiang Y, et al. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in china. Ophthalmology. 2017;124(3):408\u20139.","journal-title":"Ophthalmology"},{"issue":"3","key":"402_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000449530","volume":"236","author":"E Alyama\u00e7 Sukgen","year":"2016","unstructured":"Alyama\u00e7 Sukgen E, \u00c7\u00f6mez A, Ko\u00e7luk Y, Cevher S. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016;236(3):139\u201347.","journal-title":"Ophthalmologica"},{"issue":"4","key":"402_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol. 2014;98(4):507\u201312.","journal-title":"Br J Ophthalmol"},{"key":"402_CR28","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0161-6420(01)00660-1","volume":"108","author":"RS Kaiser","year":"2001","unstructured":"Kaiser RS, Trese MT, Williams GA, Cox MS. Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears. Ophthalmology. 2001;108:1647\u201353.","journal-title":"Ophthalmology"},{"issue":"4","key":"402_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M. Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina. 2018;38(4):764\u201372.","journal-title":"Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-022-00402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-022-00402-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-022-00402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T11:41:09Z","timestamp":1659440469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-022-00402-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1186\/s40942-022-00402-3","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"7 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Research Ethics Board of the King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia (RC19\/488\/R, 1-January-2020). Written informed consent was obtained from all parents who fully understood the procedure and the purpose of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consents obtained from all parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}